To The Moon

$Hims & Hers Health Inc.(HIMS)$ entered Australia on August 31 by converting Eucalyptus’s Pilot men’s-health platform to the Hims brand. The launch expands the addressable market and reduces dependence on US regulation, but international growth is arriving while consolidated margins and cash flow are moving in the wrong direction.

The Australian offering initially covers sexual health, weight loss and hair loss, with access to branded GLP-1 medicines where clinically appropriate. Management says the expansion supports a path to $1 billion of international annual revenue within three years. The event happened and was announced on August 31; it followed the closing of the Eucalyptus acquisition in June. Hims & Hers’ official Australian announcement confirms the timing and target, while Reuters’ August 31 report describes the initial product range.

The bullish thesis is that Hims is building a global consumer-health distribution system rather than a single US telehealth product. The platform combines advertising, digital intake, clinician access, prescriptions and fulfilment. That vertical integration can support personalised treatment plans across weight loss, dermatology, sexual health and hormonal care. Rebranding an existing Australian business is also less risky than entering with no subscribers, clinicians or local operating knowledge.

Growth remains strong. For the quarter ended June 30 and reported August 10, revenue increased 38% to $753.2 million and subscribers rose 19% to almost 2.9 million. Domestic revenue growth reaccelerated to 16%, while international revenue increased more than seventeenfold after Eucalyptus joined the group. Management raised full-year revenue guidance to $3.1–$3.3 billion and retained long-term targets of at least $6.5 billion of revenue and $1.3 billion of adjusted EBITDA in 2030. The official second-quarter release provides those results and targets.

The bearish evidence is in the income statement. Gross margin fell to 64% from 76%, a twelve-percentage-point contraction. Hims reported an $86.3 million GAAP net loss, versus $42.5 million of profit a year earlier; adjusted EBITDA declined to $60.3 million from $82.2 million, and free cash flow was negative $68.2 million. Acquisition costs, legal contingencies, product mix and the US weight-loss restructuring explain portions of the decline, but they still consume shareholder capital.

Regulation remains the largest non-financial risk. On February 6, the FDA announced plans to restrict active ingredients used in non-approved compounded GLP-1 drugs and specifically named Hims & Hers among companies mass-marketing them. Hims has shifted toward branded medicines and says compounded access will be limited, but branded drugs normally offer less room for vertical margin capture. The FDA’s February 6 announcement is the authoritative source for that enforcement stance.

HIMS closed at $29.58 on August 31, up 2.6%, after trading from approximately $28.63 to $29.79 on 8.3 million shares. It added another 0.4% to approximately $29.70 after hours. Volume was only about half its recent average, so the Australia announcement produced a positive but not decisive breakout.

Support lies at $28–$28.50 and then $25.50–$26. Resistance is $30, followed by $32 and $35. The very wide 52-week range and elevated short interest underline how quickly sentiment can reverse.

If HIMS closes above $30 and subsequently holds $29 during a retest, a 30–45-day $25/$22.50 bull put spread, or liquid strikes with the short put around 0.10–0.15 live delta, would place defined risk below the current base. Because short interest and regulatory headlines can produce gaps, a naked short put would carry materially greater tail risk. A close below $26 or new FDA action that disrupts the branded transition would invalidate the spread. Maximum loss equals the $2.50 width minus the credit received.

The evidence leans neutral. International distribution and subscriber growth are valuable, but the margin decline, negative cash flow and unresolved US regulatory exposure prevent a bullish conclusion. The view would become bullish if domestic growth remains above the mid-teens while gross margin and free cash flow recover; it would turn bearish if Australia requires persistent subsidies, FDA action disrupts weight-loss revenue or HIMS loses $26. This is personal opinion for education and is not financial advice; it is not an instruction to enter any trade.